^
    Back
    Association details:
    Biomarker:PARD3 overexpression
    Cancer:Breast Cancer
    Drug:paclitaxel (Tubulin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Breast Cancer Res Treat
    Title:

    Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest

    Published date:
    01/26/2022
    Excerpt:
    Par3 over-expression significantly sensitized breast cancer cells to paclitaxel by promoting cell apoptosis and reducing cell proliferation.
    DOI:
    10.1007/s10549-021-06490-3